



## AMENDMENT

### Listing of the Claims

This listing of claims replaces all previous listings or versions thereof:

1. (Presently Amended) A pharmaceutical composition, comprising an imexon or derivative thereof in combination with one or more ~~lipids~~ phospholipids.
2. (Presently Amended) The pharmaceutical composition of claim 1, wherein at least a portion of the ~~lipids~~ phospholipids comprise micelles.
3. (Canceled)
4. (Presently Amended) The pharmaceutical composition of claim 3, wherein a portion of the ~~lipids~~ phospholipids comprise liposomes.
5. (Original) The pharmaceutical composition of claim 1, wherein the phospholipid is dimyristoyl phosphatidyl choline, dimyristoylphosphatidylglycerol or phosphatidic acid.
6. (Original) The pharmaceutical composition of claim 1, comprising a plurality of phospholipids.
7. (Original) The pharmaceutical composition of claim 6, wherein the phospholipids comprise dimyristoyl phosphatidyl choline and dimyristoylphosphatidylglycerol.
8. (Original) The pharmaceutical composition of claim 7, further defined as comprising dimyristoyl phosphatidyl choline and dimyristoylphosphatidylglycerol in a 7:3 molar ratio.
9. (Original) The pharmaceutical composition of claim 6, wherein the plurality of lipids comprise dimyristoyl phosphatidyl choline and phosphatidic acid.
10. (Original) The pharmaceutical composition of claim 9, further defined as comprising dimyristoyl phosphatidyl choline and phosphatidic acid in a 7:1 molar ratio.

11. (Presently Amended) The pharmaceutical composition of claim 1, wherein the imexon or derivative thereof is hydrophobic.
12. (Original) The pharmaceutical composition of claim 1, wherein composition comprises imexon.
13. (Original) The pharmaceutical composition of claim 1, wherein the composition comprises at least one derivative of imexon.
14. (Presently Amended) The pharmaceutical composition of claim 13, wherein the derivative of imexon comprises ~~AMP-404~~ 2-cyanoaziridine-1-(N-benzyl) carboxamide.
15. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-404~~ 2-cyanoaziridine-1-(N-benzyl) carboxamide.
16. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-408~~ 2-cyanoaziridine-1-[N-(3,4-dichlorophenyl)] carboxamide.
17. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-415~~ 2-cyanoaziridine-1-[N-(4-fluorophenyl)] carboxamide.
18. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-416~~ 2-cyanoaziridine-1-[N-(4-trifluorophenyl)] carboxamide.
19. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-419~~ 2-cyanoaziridine-1-[N-(4-ethoxycarbonylphenyl)] carboxamide.
20. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP-420~~ 2-cyanoaziridine-1-[N-(ethoxycarbonyl)methyl] carboxamide.

21. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP 421~~ 2-cyanoaziridine-1-[N-(3-pyridyl)] carboxamide.
22. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP 423~~ 2-cyanoaziridine-1-[N-(1-naphthyl)] carboxamide.
23. (Presently Amended) The pharmaceutical composition of claim 11, wherein the derivative of imexon comprises ~~AMP 425~~ 2-cyanoaziridine-1-[N-(3-acetylphenyl)] carboxamide.
24. (Presently Amended) The pharmaceutical composition of claim 13, wherein the derivative of imexon comprises ~~AMP 403, AMP 405, AMP 406, AMP 407, AMP 408, AMP 409, AMP 410, AMP 412, AMP 413, AMP 414, AMP 417, AMP 418, AMP 419, AMP 420, AMP 421, AMP 422, AMP 423, AMP 424 or AMP 425~~ 2-cyanoaziridine-1-(N-methyl) carboxamide, 2-cyanoaziridine-1-[N-carbonic dichloride] carboxamide [Check this chemical formula], 2-cyanoaziridine-1-(N-ethyl)carboxamide, 2-cyanoaziridine-1-[N-(2,4-dichlorophenyl)] carboxamide, 2-cyanoaziridine-1-[N-(3,4-dichlorophenyl)] carboxamide, 2-cyanoaziridine-1-carboxamide (intermediate) [Check this chemical formula], 2-cyanoaziridine-1-(N-*t*-butyl) carboxamide, 2-cyanoaziridine-1-(N-phenyl) carboxamide, 2-cyanoaziridine-1-(N-cyclohexyl) carboxamide, 2-cyanoaziridine-1-(N-butyl) carboxamide, 2-cyanoaziridine-1-[N-(*p*-nitrophenyl)] carboxamide, 2-cyanoaziridine-1-[N-(*bis*-cyanoaziridine)] carboxamide, 2-cyanoaziridine-1-[N-(4-ethoxycarbonylphenyl)] carboxamide, 2-cyanoaziridine-1-[N-(ethoxycarbonyl)methyl] carboxamide, 2-cyanoaziridine-1-[N-(3-pyridyl)] carboxamide, 2-cyanoaziridine-1-[N-(4-sulfamylphenyl)] carboxamide, 2-cyanoaziridine-1-[N-(1-naphthyl)]carboxamide, 2-cyanoaziridine-1-[N-(2-acetoxyphenyl)] carboxamide or 2-cyanoaziridine-1-[N-(3-acetylphenyl)] carboxamide.

25. (Original) The pharmaceutical composition of claim 1, further comprising a targeting agent, a diagnostic agent or a second therapeutic agent.
26. (Presently Amended) The pharmaceutical composition of claim 25, wherein said targeting agent, diagnostic agent or second therapeutic agent is covalently attached to said ~~lipids~~ phospholipids by a linking moiety.
27. (Original) The pharmaceutical composition of claim 25, comprising a second therapeutic agent.
28. (Original) The pharmaceutical composition of claim 26, wherein said second therapeutic agent comprises an anticancer agent.
29. (Original) The pharmaceutical composition of claim 28, wherein the anticancer agent is chemotherapy agent, a radiotherapy agent, an immune therapy agent, a genetic therapy agent, a hormonal therapy agent or a biological agent.
30. (Presently Amended) A pharmaceutical liposome composition, comprising an imexon or a derivative thereof in combination with one or more ~~lipids~~ phospholipids.
31. (Presently Amended) A method of treating an individual with cancer, comprising administering to said individual a therapeutically effective amount of a composition comprising an imexon or derivative thereof in combination with one or more ~~lipids~~ phospholipids.
32. (Presently Amended) A method of stimulating the immune system of an individual, comprising administering a therapeutically effective amount of a composition comprising an imexon or derivative thereof in combination with one or more ~~lipids~~ phospholipids.